Core Viewpoint - First Shanghai maintains a "Buy" rating for Shenzhou International (02313) with a target price of HKD 79.80, highlighting the company's strong performance despite fluctuations in the sports brand and macroeconomic environment [1] Group 1: Financial Performance - For the first half of 2025, the company's revenue increased by 15.3% to RMB 14.97 billion, driven primarily by volume growth, while prices in USD decreased by 0.8% [1] - Gross margin declined by 1.9 percentage points to 27.1%, mainly due to increased employee compensation in the second half of the previous year [1] - The company recorded a net profit attributable to shareholders growth of 8.4% to RMB 3.18 billion, with overall revenue growth exceeding expectations [1] Group 2: Product and Market Performance - The sports category grew by 9.9%, while the leisure category saw a significant increase of 37.4%, driven by demand in the US, Europe, and Japan [2] - Regional performance showed Europe, the US, Japan, and other regions growing by 19.9%, 35.8%, 18.1%, and 18.7% respectively, while the domestic market declined by 2.1% [2] - The growth of major clients like Nike, Adidas, Uniqlo, and Puma was 6.0%, 28.2%, 27.4%, and 14.7% respectively, with their combined market share increasing by 2.7 percentage points to 82.1% [2] Group 3: Future Outlook and Capacity - The company expects high single-digit growth in volume for the second half of the year, with an improvement in gross margin due to faster growth in sports products [3] - In terms of capacity, the company has recruited 4,000 employees in Cambodia in the first half and plans to hire a total of 6,000 by year-end, while the acquisition of a factory in Vietnam will increase daily capacity by 200-300 tons [3] - Capital expenditure for the first half was RMB 1.5 billion, with an estimated total of around RMB 2.3 billion for the year [3]

Core Viewpoint - The report maintains a "Buy" rating for Bruker (00325), projecting Non-GAAP net profits of 725 million, 998 million, and 1.268 billion yuan for 2025-2027, with a target price of 123.6 HKD, indicating a potential upside of 30.1% from the current stock price [1] Revenue Performance - In the first half of 2025, the company achieved revenue of 1.348 billion yuan, a year-on-year increase of 27.9%, with a net profit of 297 million yuan, returning to profitability [1] - Adjusted net profit reached 320 million yuan, up 9.6% year-on-year, with an adjusted net profit margin of 23.9%, down 4.0 percentage points [1] Product Category Growth - The sales revenue of building block role-playing toys was 1.325 billion yuan, up 29.5% year-on-year, with sales volume increasing by 96.8% to 111 million units, while the average price decreased by 33.5% to 12.0 yuan [1] - The sales of building block toys declined by 45.5% year-on-year, with sales volume down 42.9% to 100 thousand units [1] - Other products generated revenue of 330 thousand yuan, a year-on-year increase of 111.5% [1] Channel Performance - Offline sales through distributors reached 1.212 billion yuan, up 26.5% year-on-year, accounting for 90.6% of total sales [2] - Online sales amounted to 108 million yuan, a year-on-year increase of 44.6%, representing 8.1% of total sales, driven by increased sales among consumers aged 16 and above [2] Geographic Revenue Growth - Domestic revenue was 1.226 billion yuan, up 18.5% year-on-year, while overseas revenue surged to 111 million yuan, a staggering increase of 898.6%, accounting for 8.3% of total revenue [3] - Revenue from Asia (excluding China), North America, and other overseas regions grew by 652.5%, 2135.9%, and 594.7% respectively [3] IP Structure and User Demographics - The company is diversifying its IP matrix to reduce reliance on single IPs, with the top four IPs contributing over 10% each, totaling 83.1% of revenue, compared to 92.3% for the top three IPs last year [4] - The revenue contribution from products targeting consumers aged 16 and above increased to 14.8%, up 4.4 percentage points year-on-year, while the core revenue source remains products for ages 6-16, accounting for 82.6% [4] Profitability and Investment - The gross profit margin for the first half of 2025 was 48.4%, down 4.5 percentage points year-on-year, attributed to a higher proportion of lower-margin new products and increased depreciation from more molds [5] - Sales, R&D, and management expense ratios were 13.2%, 9.6%, and 3.5% respectively, with sales expenses rising due to increased marketing for new products and a growing sales team [5] - R&D expenses increased significantly due to a rise in personnel, with the R&D team growing by 81.0% to 599 members [5]

Core Viewpoint - The company maintains a "buy" rating for Bruker (00325) with a target price of HKD 123.6, indicating a potential upside of 30.1% from the current stock price, based on projected Non-GAAP net profits of 725 million, 998 million, and 1.268 billion for the years 2025-2027 [1] Revenue and Profitability - In the first half of 2025, the company achieved revenue of 1.348 billion, a year-on-year increase of 27.9%, with a net profit of 297 million, turning positive compared to the previous year [1] - Adjusted net profit reached 320 million, reflecting a 9.6% increase year-on-year, with an adjusted net profit margin of 23.9%, down 4.0 percentage points from the previous year [1] Product Performance - The sales revenue for building block toys decreased by 45.5% to 13 million, with a volume drop of 42.9% to 100,000 units, while the sales of character-based toys increased by 29.5% to 1.325 billion, with a significant volume increase of 96.8% to 111 million units [2] - The average price of character-based toys fell by 33.5% to 12.0, primarily due to the introduction of a new budget product priced at 9.9, which contributed 216 million in revenue [2] Sales Channels - Offline sales accounted for 90.6% of total sales, reaching 1.212 billion, a 26.5% increase year-on-year, while online sales grew by 44.6% to 108 million, representing 8.1% of total sales [3] Geographic Performance - Domestic revenue was 1.226 billion, up 18.5% year-on-year, while overseas revenue surged by 898.6% to 111 million, now accounting for 8.3% of total revenue [4] - Revenue from Asia (excluding China), North America, and other overseas regions saw significant growth, with increases of 652.5%, 2135.9%, and 594.7% respectively [4] IP and User Demographics - The company has diversified its IP structure, reducing reliance on single IPs, with the top four IPs contributing over 10% each, totaling 83.1% of revenue [5] - The revenue share from products targeting consumers aged 16 and above increased to 14.8%, while the core revenue source remains products for ages 6-16, accounting for 82.6% [5] Cost Structure and Investment - The gross margin for the first half of 2025 was 48.4%, down 4.5 percentage points, attributed to changes in product mix and increased depreciation from new molds [6] - Sales, R&D, and management expense ratios were 13.2%, 9.6%, and 3.5% respectively, with increases in sales and R&D expenses due to new product promotions and a growing R&D team [6]

Core Viewpoint - First Shanghai maintains a "buy" rating for Kangchen Pharmaceutical (01681) and adjusts the profit forecast for 2025-2027, setting a target price of HKD 25.20, indicating a potential upside of 59.50% from the current price [1] Financial Performance - Kangchen Pharmaceutical reported a revenue of RMB 1.569 billion for the first half of 2025, representing a year-on-year growth of 23.7% [2] - Gross profit increased by approximately 27.6% to RMB 1.209 billion, with a gross margin of 77.1%, up 2.4 percentage points from the same period in 2024, mainly due to a decrease in raw material prices [2] - Shareholders' profit attributable to the company was approximately RMB 498 million, a year-on-year increase of 24.6% [2] - The company continues its high dividend policy, proposing an interim dividend of HKD 0.33 per share, with a payout ratio exceeding 51% [2] Product and Business Development - The sales revenue of nephrology drugs reached approximately RMB 1.131 billion, a year-on-year increase of about 28.0%, driven by the core product, Uremia Qing granules, which maintains a leading position in the modern Chinese medicine category for kidney diseases [3] - Sales revenue from pediatric and women's drugs was approximately RMB 172 million, up about 17.5% year-on-year, with the unique oral iron supplement, Yuanlikang, entering the national essential drug and medical insurance catalog [3] - The medical imaging contrast agent series generated sales of approximately RMB 95 million, a year-on-year increase of about 22.0% [3] - The company has launched new CT contrast agents and has a rich pipeline of products under development [3] Market Position and Competitive Advantage - Uremia Qing granules are the flagship product of Kangchen Pharmaceutical, holding a leading position in the kidney disease Chinese medicine market, with a significant target market due to the high prevalence of chronic kidney disease (CKD) in China [4] - The product is the first kidney disease Chinese medicine to complete evidence-based medical research and has received strong recommendations in multiple clinical guidelines [4] - Despite the expiration of the product's patent in 2024, the complexity of its compound formulation and stringent drug approval processes are expected to maintain high market barriers and a concentrated competitive landscape [5]

Core Viewpoint - First Shanghai maintains a "buy" rating for Kangchen Pharmaceutical (01681) and adjusts the profit forecast for 2025-2027, setting a target price of HKD 25.20, indicating a potential upside of 59.50% from the current price [1] Group 1: Overall Performance - Kangchen Pharmaceutical demonstrated strong performance in the first half of 2025, with revenue reaching RMB 1.569 billion, a year-on-year increase of 23.7% [1] - Gross profit grew approximately 27.6% to RMB 1.209 billion, with a gross margin of 77.1%, up 2.4 percentage points from the same period in 2024, attributed to lower raw material costs [1] - Shareholder profit attributable to the company was approximately RMB 498 million, a year-on-year increase of 24.6%, with a proposed interim dividend of HKD 0.33 per share, resulting in a payout ratio exceeding 51% [1] Group 2: Core Product Growth - Revenue from nephrology drugs reached approximately RMB 1.131 billion, a year-on-year increase of about 28.0%, driven by the core product, Uremia Qing granules, which maintains a leading position in the modern Chinese medicine category for kidney disease [2] - Revenue from pediatric and women's health drugs was approximately RMB 172 million, a year-on-year increase of about 17.5%, with the unique oral iron supplement, Yuanlikang, gaining market share after the removal of reimbursement restrictions [2] - Sales of medical imaging contrast agents reached approximately RMB 95 million, a year-on-year increase of about 22.0%, with multiple new products launched and a rich pipeline of products under development [2] Group 3: Leading Position in Nephrology - Uremia Qing granules are the flagship product of Kangchen Pharmaceutical, holding a leading position in the kidney disease Chinese medicine market, with a unique competitive advantage [3] - The product is primarily used for chronic kidney disease (CKD), effectively lowering serum creatinine levels and delaying the progression of CKD, with a high safety profile [3] - The prevalence of CKD in Chinese adults is as high as 8.2%, with an estimated patient population exceeding 120 million, indicating a substantial target market [3] Group 4: Market Dynamics and Future Outlook - Uremia Qing granules have a broad range of indications and high clinical application frequency, supported by a strong sales and public relations team [4] - The product is included in the medical insurance directory, making it affordable, and the company has adopted a "price for volume" strategy to consolidate and enhance market share [4] - Despite the expiration of the product's patent in 2024, the complexity of its compound formulation and stringent drug approval processes are expected to maintain high market barriers and a concentrated competitive landscape [4]

Core Viewpoint - First Shanghai maintains a "buy" rating for NetDragon (00777), highlighting the stability of the company's gaming business and the potential of its education business market space [1] Group 1: 2025 Mid-Year Performance - NetDragon is projected to achieve revenue of 2.38 billion RMB in the first half of 2025, with a gross profit of 1.7 billion RMB, reflecting a gross margin increase of 2.9 percentage points to 69.5% year-on-year [2] - Operating expenses are expected to be 1.35 billion RMB, a decrease of 15.6% year-on-year, indicating the effectiveness of the company's cost optimization and efficiency improvement measures [2] - The company has a solid financial position with net cash of approximately 1.5 billion RMB and holds 12,000 Ethereum as digital asset reserves [2] - A mid-term dividend of 0.5 HKD per share has been announced, with a commitment to return at least 600 million HKD to shareholders through dividends and share buybacks over the next year [2] Group 2: Gaming Business - In the first half of 2025, the gaming and other businesses generated revenue of 1.74 billion RMB, showing signs of stabilization compared to the second half of 2024 [3] - The Monthly Active Users (MAU) of "Magic Domain" increased by 11% year-on-year, with mobile revenue also showing a quarter-on-quarter increase, indicating improved user engagement and retention [3] - The operating profit margin for the gaming business has rebounded to 28.8%, nearing historical normal levels [3] - Upcoming product launches include "Code MY" which began small-scale testing in August, and plans to expand "Magic Domain" and "Code Alpha" into multiple overseas markets [3] Group 3: Education Business - The Mynd.ai business generated revenue of 640 million RMB in the first half of 2025 [4] - In response to challenges from reduced global education technology spending, the company will continue to pursue cost optimization [4] - Despite weak performance in traditional markets in Europe and the US, the company is actively exploring emerging markets for new growth opportunities [4] - While short-term pressures from fluctuations in overseas education budgets remain, the long-term logic of increasing global education digital penetration remains unchanged [4]

Core Viewpoint - First Shanghai maintains a "buy" rating for NetDragon (00777), highlighting the robustness of the company's gaming business and the potential market space for its education business. The steady development of gaming IPs and the expansion into overseas markets, along with the successful promotion of tablet products, are expected to drive new performance growth for the company. The target price is set at HKD 17.27, indicating a 55% upside from the previous closing price [1] Group 1: 2025 Mid-Year Performance - NetDragon is projected to achieve revenue of RMB 2.38 billion in the first half of 2025, with a gross profit of RMB 1.7 billion and a gross margin increase of 2.9 percentage points to 69.5%, reflecting enhanced overall profitability [1] - Operating expenses are expected to be RMB 1.35 billion, a decrease of 15.6% year-on-year, indicating the effectiveness of cost optimization and efficiency improvement measures [1] - The company has a solid financial position with net cash of approximately RMB 1.5 billion and holds 12,000 Ethereum as part of its digital asset reserves [1] - A mid-term dividend of HKD 0.5 per share has been announced, with a commitment to return at least HKD 600 million to shareholders through dividends and share buybacks over the next year [1] Group 2: Gaming Business - In the first half of 2025, the gaming and other businesses generated revenue of RMB 1.74 billion, showing signs of stabilization and recovery compared to the second half of 2024 [2] - The Monthly Active Users (MAU) of "Magic Domain" increased by 11% year-on-year, with mobile revenue also showing a quarter-on-quarter increase, indicating improved user engagement and retention [2] - The operating profit margin for the gaming business has rebounded to 28.8%, nearing historical normal levels, due to ongoing cost reduction and efficiency enhancement efforts [2] - Upcoming product launches include "Code MY" which began small-scale testing in August, and plans to launch "Magic Domain" and "Code Alpha" in multiple overseas markets in the second half of the year [2] Group 3: Education Business - The Mynd.ai business generated revenue of RMB 640 million in the first half of 2025 [3] - In response to challenges from reduced global education technology spending, the company will continue to pursue cost optimization [3] - Despite weak performance in traditional markets in Europe and the US, the company is actively exploring emerging markets for new growth opportunities [3] - While short-term pressures from fluctuations in overseas education budgets remain, the long-term core logic of increasing digital penetration in global education remains unchanged [3]

Core Viewpoint - The report maintains a "Buy" rating for China Resources Vientiane Life (01209), projecting net profit for the years 2025-2027 to be 4.0 billion, 4.6 billion, and 5.26 billion respectively, with a target price of 48.5 HKD [1] Financial Performance - In the first half of 2025, the company's revenue reached 8.524 billion, a year-on-year increase of 6.5%, with a gross margin of 37.1%, up 3.1 percentage points [2] - Core net profit increased by 15.0% to 2.01 billion, with a core net profit margin rising by 1.4 percentage points to 23.6% [2] - The proposed interim dividend is 0.53 per share, along with a special dividend of 0.35 per share, resulting in a 100% payout ratio based on core net profit [2] Commercial Management - Commercial management revenue was 3.27 billion, a year-on-year increase of 14.6%, with a gross margin improvement of 5.2 percentage points to 66.1% [3] - Retail sales in shopping centers grew by 21.1% to 122 billion, with same-store sales increasing by 9.7%, outperforming the overall retail sales growth [3] - The company operated 125 shopping centers with an average occupancy rate of 97.1%, an increase of 0.4 percentage points from the end of 2024 [3] Property Management - Property management revenue grew by 1.1% to 5.16 billion, with a slight decline in gross margin to 18.8% due to a decrease in community space service income [4] - The total contracted area reached 4.5 billion square meters, with managed area increasing by 0.4% to 4.2 billion square meters [4] - The urban space segment's managed area grew by 1.8% to 1.27 billion square meters, accounting for 30.2% of the total managed area, with revenue contribution rising to 18.4% [4]

Core Viewpoint - First Shanghai maintains a "Buy" rating for China Resources Vientiane Life (01209), projecting net profit attributable to shareholders of 4.0 billion, 4.6 billion, and 5.26 billion yuan for 2025-2027, with a target price of 48.5 HKD [1] Group 1: Financial Performance - In the first half of 2025, the company's revenue reached 8.524 billion yuan, a year-on-year increase of 6.5% [1] - Core net profit increased by 15.0% to 2.01 billion yuan, with a core net profit margin rising by 1.4 percentage points to 23.6% [1] - The company plans to distribute an interim dividend of 0.53 yuan per share and a special dividend of 0.35 yuan per share, achieving a 100% payout ratio based on core net profit [1] Group 2: Commercial Management - Commercial management revenue was 3.27 billion yuan, up 14.6% year-on-year, with a gross margin increase of 5.2 percentage points to 66.1% [2] - Retail sales in shopping centers grew by 21.1% to 122 billion yuan, with same-store sales increasing by 9.7% [2] - The company operated 125 shopping centers at the end of the period, maintaining an average occupancy rate of 97.1%, an increase of 0.4 percentage points from the end of 2024 [2] Group 3: Property Management - Property management revenue grew by 1.1% to 5.16 billion yuan, with a slight decline in gross margin by 0.1 percentage points to 18.8% [3] - Urban space revenue increased by 15.1%, contributing to a rise in the proportion of urban space in total managed area to 30.2% [3] - The total managed area reached 4.2 billion square meters, with urban space managed area growing by 1.8% to 1.27 billion square meters [3]

公司作为财险行业龙头，规模以及成本优势放大，马太效应加剧。公司上半年的业绩展示了其强大的α 能力。在行业平稳的背景下，公司通过内部管理的精益化和风险定价的科学化，实现了盈利能力的内生 性强劲增长。这一趋势有望在下半年延续，支撑公司全年业绩的高质量增长。公司作为港股唯一纯财险 标的，盈利模式可持续性强且公司长期ROE、股息率保持稳定，具备长期投资价值。 报告中称，公司2025年上半年实现保险服务收入2490亿元，同比增长5.6%;其中车险业务实现保险服务 收入1503亿元，同比增长3.5%;非车险保险服务收入987亿元，同比增长8.8%;上半年实现净利润高达245 亿元，同比增长32.3%。剔除投资波动影响的承保利润达到130亿元，同比大幅增长44.6%，这标志着公 司核心业务的盈利能力达到了新的高度。公司上半年净资产较年初增长7.9%，中期拟派息0.24元/股， 同比增长15.4%。 第一上海发布研报称，予中国财险(02328)"买入"评级，预计2025-2027年公司归母净利润分别为 450/477/515亿元，同比增长35.9%/5.7%/8.1%，目标价22.2港元。 ...